{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:18:16Z","timestamp":1782181096362,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00347-022-01751-y","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T18:08:41Z","timestamp":1667844521000},"page":"1129-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Kardiovaskul\u00e4re Risikofaktoren, Gerinnung und gerinnungswirksame Therapien bei retinalen Gef\u00e4\u00dfverschlusserkrankungen","Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion"],"prefix":"10.1007","volume":"119","author":[{"given":"Claudia","family":"Kuhli-Hattenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Schultheiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Olof","family":"Hattenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"1751_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1160\/TH04-10-0659","volume":"94","author":"S Ars\u00e9ne","year":"2005","unstructured":"Ars\u00e9ne\u00a0S, Delahousse\u00a0B, Regina\u00a0S, Le Lez\u00a0M\u2011L, Pisella\u00a0P\u2011J, Gruel\u00a0Y (2005) Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60\u00a0years of age. Thromb Haemost 94:101\u2013106","journal-title":"Thromb Haemost"},{"key":"1751_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-2008-1045968","volume":"198","author":"B Bertram","year":"1991","unstructured":"Bertram\u00a0B, Wolf\u00a0S, Fisches\u00a0H, Schulte\u00a0K, Hoberg\u00a0A, Reim\u00a0M (1991) Lysebehandlung bei retinalen Arterienverschl\u00fcssen mit Plasminogen-Aktivator. Klin Monatsbl Augenheilkd 198:295\u2013300","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1751_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0889-8588(02)00101-6","volume":"17","author":"RL Bick","year":"2003","unstructured":"Bick\u00a0RL (2003) Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. Hematol Oncol Clin North Am 17:9\u201336","journal-title":"Hematol Oncol Clin North Am"},{"key":"1751_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.23736\/S0026-4725.19.04891-6","volume":"67","author":"G Belcaro","year":"2019","unstructured":"Belcaro\u00a0G, Dual\u00a0M, Bradford\u00a0HD et\u00a0al (2019) Recurrent retinal vein thrombosis: Prevention with aspirin, pycnogenol, ticlopidine, or sulodexide. Minerva Cardioangiol 67:109\u2013114","journal-title":"Minerva Cardioangiol"},{"key":"1751_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/17474086.2016.1249364","volume":"9","author":"E Campello","year":"2016","unstructured":"Campello\u00a0E, Spiezia\u00a0L, Simioni\u00a0P (2016) Diagnosis and management of factor V Leiden. Expert Rev Hematol 9:1139\u20131149","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"1751_CR6","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2015.05.044","volume":"122","author":"J Callizo","year":"2015","unstructured":"Callizo\u00a0J, Feltgen\u00a0N, Pantenburg\u00a0S et\u00a0al (2015) Cardiovascular risk factors in central retinal artery occlusion: Results of a\u00a0prospective and standardized medical examination. Ophthalmology 122(9):1881\u20131888. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.044","journal-title":"Ophthalmology"},{"key":"1751_CR7","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1161\/STROKEAHA.111.613653","volume":"42","author":"CS Chen","year":"2011","unstructured":"Chen\u00a0CS, Lee\u00a0AW, Campbell\u00a0B et al (2011) Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a\u00a0randomized, controlled trial. Stroke 42:2229\u20132234","journal-title":"Stroke"},{"issue":"6","key":"1751_CR8","doi-asserted-by":"publisher","first-page":"BIO82","DOI":"10.1167\/iovs.17-21413","volume":"58","author":"KH Cho","year":"2017","unstructured":"Cho\u00a0KH, Kim\u00a0CK, Oh\u00a0K, Oh\u00a0SW, Park\u00a0KH, Park\u00a0SJ (2017) Retinal vein occlusion as the surrogate marker for premature brain aging in young patients. Invest Ophthalmol Vis Sci 58(6):BIO82\u2013BIO87. https:\/\/doi.org\/10.1167\/iovs.17-21413","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1751_CR9","doi-asserted-by":"publisher","first-page":"e248425","DOI":"10.1136\/bcr-2021-248425","volume":"15","author":"RA Chowdhary","year":"2022","unstructured":"Chowdhary\u00a0RA, Siddiqui\u00a0MAR, Moiz\u00a0B, Ishaq\u00a0S (2022) Combined central retinal artery and vein occlusion associated with antiphospholipid syndrome. BMJ Case Rep 15:e248425. https:\/\/doi.org\/10.1136\/bcr-2021-248425","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1751_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12872-018-0825-1","volume":"18","author":"CB Christiansen","year":"2018","unstructured":"Christiansen\u00a0CB, Torp-Pedersen\u00a0C, Olesen\u00a0JB et al (2018) Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a\u00a0nationwide cohort study. BMC Cardiovasc Disord 18(1):91. https:\/\/doi.org\/10.1186\/s12872-018-0825-1","journal-title":"BMC Cardiovasc Disord"},{"key":"1751_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00347-003-0820-4","volume":"100","author":"S Dithmar","year":"2003","unstructured":"Dithmar\u00a0S, Hansen\u00a0LL, Holz\u00a0FG (2003) Ven\u00f6se retinale Verschl\u00fcsse. Ophthalmologe 100:561\u2013177","journal-title":"Ophthalmologe"},{"key":"1751_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1160\/TH07-01-0007","volume":"97","author":"S Fateh-Moghadam","year":"2007","unstructured":"Fateh-Moghadam\u00a0S, Kawa\u00a0M (2007) Retinal vein occlusion disease and platelet activation: Will anti platelet therapy be a\u00a0promising therapeutic strategy for patients with retinal vein occlusion disease in the future? Thromb Haemost 97:169\u2013170.9","journal-title":"Thromb Haemost"},{"key":"1751_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00417-005-0140-2","volume":"244","author":"N Feltgen","year":"2006","unstructured":"Feltgen\u00a0N, Neubauer\u00a0A, Jurklies\u00a0B et\u00a0al (2006) Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol 244:950\u2013956","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1751_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1442-9071.1996.tb01581.x","volume":"24","author":"SL Graham","year":"1996","unstructured":"Graham\u00a0SL, Goldberg\u00a0I, Murray\u00a0B, Beaumont\u00a0P, Chong\u00a0BH (1996) Activated protein C resistance\u2014Low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust N Z J Ophthalmol 24:199\u2013205","journal-title":"Aust N Z J Ophthalmol"},{"key":"1751_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1055\/s-0038-1656119","volume":"77","author":"JC Gris","year":"1997","unstructured":"Gris\u00a0JC, Ripart-Neveu\u00a0S, Maugard\u00a0C et al (1997) Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 77:1096\u20131103","journal-title":"Thromb Haemost"},{"key":"1751_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ajo.2008.06.016","volume":"146","author":"LO Hattenbach","year":"2008","unstructured":"Hattenbach\u00a0LO, Kuhli-Hattenbach\u00a0C, Scharrer\u00a0I et al (2008) Intravenous thrombolysis with low dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol 146:700\u2013706","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1751_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/IAE.0b013e3181a3b870","volume":"29","author":"LO Hattenbach","year":"2009","unstructured":"Hattenbach\u00a0LO, Arndt\u00a0CF, Lerche\u00a0R (2009) Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a\u00a0prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 29(7):932\u2013940","journal-title":"Retina"},{"key":"1751_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0014-4835(03)00214-8","volume":"78","author":"SS Hayreh","year":"2004","unstructured":"Hayreh\u00a0SS, Zimmerman\u00a0MB, Kimura\u00a0A, Sanon\u00a0A (2004) Central retinal artery occlusion. Retinal survival time. Exp Eye Res 78:723\u2013736","journal-title":"Exp Eye Res"},{"key":"1751_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.thromres.2020.04.005","volume":"190","author":"JL Hernandez","year":"2020","unstructured":"Hernandez\u00a0JL, Sanles\u00a0I, Perez-Montes\u00a0R et al (2020) Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion. Thromb Res 190:63\u201368","journal-title":"Thromb Res"},{"key":"1751_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/1871525719666210914112402","author":"O Karcioglu","year":"2021","unstructured":"Karcioglu\u00a0O, Yilmaz\u00a0S, Afacan\u00a0G et\u00a0al (2021) An update of the efficacy and comparative characteristics of direct (new) oral anticoagulants (DOACs). Cardiovasc Hematol Agents Med Chem. https:\/\/doi.org\/10.2174\/1871525719666210914112402","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"1751_CR21","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/archopht.120.9.1234","volume":"120","author":"JC Kattah","year":"2002","unstructured":"Kattah\u00a0JC, Wang\u00a0DZ, Reddy\u00a0C (2002) Intravenous recombinant tissue-type plasminogen activatorthrombolysis in treatment of central retinal artery occlusion. Arch Ophthalmol 120:1234\u20131236","journal-title":"Arch Ophthalmol"},{"key":"1751_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00417-001-0415-1","volume":"240","author":"C Kuhli","year":"2002","unstructured":"Kuhli\u00a0C, Hattenbach\u00a0LO, Scharrer\u00a0I, Koch\u00a0F, Ohrloff\u00a0C (2002) High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:163\u2013168","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1751_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ajo.2003.10.024","volume":"137","author":"C Kuhli","year":"2004","unstructured":"Kuhli\u00a0C, Scharrer\u00a0I, Koch\u00a0F, Ohrloff\u00a0C, Hattenbach\u00a0LO (2004) Factor XII deficiency: a\u00a0thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 137:459\u2013464","journal-title":"Am J Ophthalmol"},{"key":"1751_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archopht.124.8.1165","volume":"124","author":"C Kuhli","year":"2006","unstructured":"Kuhli\u00a0C, Jochmans\u00a0K, Scharrer\u00a0I, L\u00fcchtenberg\u00a0M, Hattenbach\u00a0LO (2006) Retinal vein occlusion associated with antithrombin deficiency secondary to a\u00a0novel G9840C missense mutation. Arch Ophthalmol 124:1165\u20131169","journal-title":"Arch Ophthalmol"},{"key":"1751_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1160\/TH09-05-0331","volume":"103","author":"C Kuhli-Hattenbach","year":"2010","unstructured":"Kuhli-Hattenbach\u00a0C, Scharrer\u00a0I, L\u00fcchtenberg\u00a0M, Hattenbach\u00a0LO (2010) Thrombophilia and the risk of retinal vein occlusion. A subgroup analysis. Thromb Haemost 103:299\u2013305","journal-title":"Thromb Haemost"},{"issue":"28","key":"1751_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/09537104.2016.1276548","volume":"2017","author":"C Kuhli-Hattenbach","year":"2017","unstructured":"Kuhli-Hattenbach\u00a0C, Hellstern\u00a0P, Kohnen\u00a0T, Hattenbach\u00a0LO (2017) Platelet activation by ADP is increased in selected patients with anterior ischemic optic neuropathy or retinal vein occlusion. Platelets 2017(28):720\u2013723","journal-title":"Platelets"},{"key":"1751_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00347-017-0456-4","volume":"114","author":"C Kuhli-Hattenbach","year":"2017","unstructured":"Kuhli-Hattenbach\u00a0C, Hellstern\u00a0P, Miesbach\u00a0W, Kohnen\u00a0T, Hattenbach\u00a0LO (2017) Multiple thrombophilic risk markers in patients <65\u00a0years of age with retinal vein occlusion. Ophthalmologe 114:1149\u20131154","journal-title":"Ophthalmologe"},{"key":"1751_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/13816810.2016.1244694","volume":"38","author":"C Kuhli-Hattenbach","year":"2017","unstructured":"Kuhli-Hattenbach\u00a0C, Hellstern\u00a0P, N\u00e4gele\u00a0DK, Kohnen\u00a0T, Hattenbach\u00a0LO (2017) Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor\u20111 polymorphism 4G\/5G and the risk of retinal vein occlusion. Ophthalmic Genet 38:413\u2013417","journal-title":"Ophthalmic Genet"},{"key":"1751_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aos.13228","volume":"95","author":"C Kuhli-Hattenbach","year":"2017","unstructured":"Kuhli-Hattenbach\u00a0C, Miesbach\u00a0W, L\u00fcchtenberg\u00a0M, Kohnen\u00a0T, Hattenbach\u00a0LO (2017) Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion. Acta Ophthalmol 95:140\u2013145","journal-title":"Acta Ophthalmol"},{"key":"1751_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0161-6420(01)00842-9","volume":"109","author":"JM Lahey","year":"2002","unstructured":"Lahey\u00a0JM, Tunc\u00a0M, Kearnea\u00a0J et\u00a0al (2002) Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56\u00a0years of age. Ophthalmology 109:126\u2013131","journal-title":"Ophthalmology"},{"key":"1751_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajo.2018.08.027","volume":"196","author":"P Lavin","year":"2018","unstructured":"Lavin\u00a0P, Patrylo\u00a0M, Hollar\u00a0M, Espaillat\u00a0KB, Kirshner\u00a0H, Schrag\u00a0M (2018) Stroke risk and risk factors in patients with central retinal artery occlusion. Am J Ophthalmol 196:96\u2013100. https:\/\/doi.org\/10.1016\/j.ajo.2018.08.027","journal-title":"Am J Ophthalmol"},{"key":"1751_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1160\/TH06-05-0257","volume":"97","author":"G Leoncini","year":"2007","unstructured":"Leoncini\u00a0G, Brutzele\u00a0D, Signorello\u00a0MG et\u00a0al (2007) Platelet activation by collagen is increased in retinal vein oculusion. Thromb Haemost 97:218\u2013227","journal-title":"Thromb Haemost"},{"key":"1751_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.thromres.2009.07.010","volume":"124","author":"G Leoncini","year":"2009","unstructured":"Leoncini\u00a0G, Signorello\u00a0MG, Armani\u00a0U, Piana\u00a0A, Ghiglione\u00a0D, Camicione\u00a0P (2009) In retinal vein occlusion platelet response to thrombin is increased. Thromb Res 124:48\u201355","journal-title":"Thromb Res"},{"issue":"12","key":"1751_CR34","doi-asserted-by":"publisher","first-page":"e004703","DOI":"10.1161\/JAHA.116.004703","volume":"5","author":"M Li","year":"2016","unstructured":"Li\u00a0M, Hu\u00a0X, Huang\u00a0J, Tan\u00a0Y, Yang\u00a0B, Tang\u00a0Z (2016) Impact of retinal vein occlusion on stroke incidence: a meta-analysis. J\u00a0Am Heart Assoc 5(12):e4703. https:\/\/doi.org\/10.1161\/JAHA.116.004703","journal-title":"J Am Heart Assoc"},{"key":"1751_CR35","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1161\/STROKEAHA.119.028743","volume":"51","author":"MB Mac Grory","year":"2020","unstructured":"Mac Grory\u00a0MB, Nackenoff\u00a0A, Poli\u00a0S et al (2020) Intravenous fibrinolysis for central retinal artery occlusion: a\u00a0cohort study and updated patient level meta-analysis. Stroke 51:2018\u20132025","journal-title":"Stroke"},{"key":"1751_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2001-14069","volume":"27","author":"T Matsuura","year":"2001","unstructured":"Matsuura\u00a0T, Kobayashi\u00a0T, Asahina\u00a0T, Kanayama\u00a0N, Terao\u00a0T (2001) Is factor XII deficiency related to recurrent miscarriage? Semin Thromb Hemost 27:115\u2013120","journal-title":"Semin Thromb Hemost"},{"key":"1751_CR37","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1161\/STROKEAHA.115.009839","volume":"46","author":"M Nedelmann","year":"2015","unstructured":"Nedelmann\u00a0M, Graef\u00a0M, Weinand\u00a0F et\u00a0al (2015) Retrobulbar spot sign predicts thrombolytic treatment effects and etiology in central retinal artery occlusion. Stroke 46:2322\u20132324","journal-title":"Stroke"},{"issue":"6","key":"1751_CR38","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.7417\/CT.2020.2269","volume":"171","author":"F Pacella","year":"2020","unstructured":"Pacella\u00a0F, Bongiovanni\u00a0G, Malvasi\u00a0M et\u00a0al (2020) Impact of cardiovascular risk factors on incidence and severity of retinal vein occlusion. Clin Ter 171(6):e534\u2013e538. https:\/\/doi.org\/10.7417\/CT.2020.2269","journal-title":"Clin Ter"},{"key":"1751_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15221","author":"G Passacquale","year":"2022","unstructured":"Passacquale\u00a0G, Sharma\u00a0P, Perera\u00a0D, Ferro\u00a0A (2022) Antiplatelet therapy in cardiovascular disease: Current status and future directions. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15221","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1751_CR40","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jth.12982","volume":"13","author":"KA Ponto","year":"2015","unstructured":"Ponto\u00a0KA, Elbaz\u00a0H, Peto\u00a0T, Laubert-Reh\u00a0D, Binder\u00a0H, Wild\u00a0PS, Lackner\u00a0K, Pfeiffer\u00a0N, Mirshahi\u00a0A (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J\u00a0Thromb Haemost 13(7):1254\u20131263. https:\/\/doi.org\/10.1111\/jth.12982","journal-title":"J Thromb Haemost"},{"key":"1751_CR41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1747493016687578","volume":"12","author":"C Preterre","year":"2017","unstructured":"Preterre\u00a0C, Godeneche\u00a0G, Vandamme\u00a0X et\u00a0al (2017) Management of acute central retinal artery occlusion: intravenous thrombolysis is feasible and safe. Int J Stroke 12:720\u2013723","journal-title":"Int J Stroke"},{"key":"1751_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3129\/i09-273","volume":"45","author":"M Rehak","year":"2010","unstructured":"Rehak\u00a0M, Krcova\u00a0V, Slavik\u00a0L, Fric\u00a0E, Langova\u00a0K, Ulehlova\u00a0J, Rehak\u00a0J (2010) The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol 45:171\u2013175","journal-title":"Can J Ophthalmol"},{"key":"1751_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1084\/jem.20050664","volume":"202","author":"T Renn\u00e9","year":"2005","unstructured":"Renn\u00e9\u00a0T, Pozgajov\u00e1\u00a0M, Gr\u00fcner\u00a0S et\u00a0al (2005) Defective thrombus formation in mice lacking coagulation factor XII. J\u00a0Exp Med 202:271\u2013281","journal-title":"J Exp Med"},{"key":"1751_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(14)76167-7","volume":"113","author":"D Schmidt","year":"1992","unstructured":"Schmidt\u00a0D, Schumacher\u00a0M, Wakhloo\u00a0AK (1992) Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 113:429\u2013434","journal-title":"Am J Ophthalmol"},{"key":"1751_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020338","author":"M Schnieder","year":"2021","unstructured":"Schnieder\u00a0M, Fischer-Wedi\u00a0CV, Bemme\u00a0S et al (2021) The Retrobulbar spot sign and prominent middle limiting membrane as prognostic markers in non-arteritic retinal artery occlusion. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm10020338","journal-title":"J Clin Med"},{"key":"1751_CR46","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1001\/jamaneurol.2015.1578","volume":"72","author":"M Schrag","year":"2015","unstructured":"Schrag\u00a0M, Youn\u00a0T, Schindler\u00a0J et al (2015) Intravenous fibrinolytic therapy in central retinal artery occlusion: a\u00a0patient-level meta-analysis. JAMA Neurol 72:1148\u20131154","journal-title":"JAMA Neurol"},{"key":"1751_CR47","doi-asserted-by":"publisher","first-page":"e198114","DOI":"10.1371\/journal.pone.0198114","volume":"13","author":"M Schultheiss","year":"2018","unstructured":"Schultheiss\u00a0M, Hartig\u00a0F, Spitzer\u00a0MS et\u00a0al (2018) Intravenous thrombolysis in acute central retinal artery occlusion\u2014A prospective interventional case series. PLoS ONE 13:e198114","journal-title":"PLoS ONE"},{"key":"1751_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000050862","volume":"215","author":"JA Scott","year":"2001","unstructured":"Scott\u00a0JA, Arnold\u00a0JJ, Currie\u00a0JM et\u00a0al (2001) No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica 215:217\u2013221","journal-title":"Ophthalmologica"},{"issue":"16","key":"1751_CR49","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1056\/NEJM200104193441607","volume":"344","author":"U Seligson","year":"2001","unstructured":"Seligson\u00a0U, Lubetsky\u00a0A (2001) Genetic susceptibility to venous thrombosis. N\u00a0Engl J Med 344(16):1222\u20131231","journal-title":"N Engl J Med"},{"issue":"1","key":"1751_CR50","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song\u00a0P, Xu\u00a0Y, Zha\u00a0M, Zhang\u00a0Y, Rudan\u00a0I (2019) Global epidemiology of retinal vein occlusion: A\u00a0systematic review and meta-analysis of prevalence, incidence, and risk factors. J\u00a0Glob Health 9(1):10427. https:\/\/doi.org\/10.7189\/jogh.09.010427","journal-title":"J Glob Health"},{"key":"1751_CR51","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1160\/TH09-09-0626","volume":"103","author":"A Squizzato","year":"2010","unstructured":"Squizzato\u00a0A, Manfredi\u00a0S, Bozzato\u00a0S et\u00a0al (2010) Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a\u00a0call for action. Thromb Haemost 103:271\u2013276","journal-title":"Thromb Haemost"},{"issue":"5\u20136","key":"1751_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10354-017-0577-z","volume":"168","author":"C Sucker","year":"2018","unstructured":"Sucker\u00a0C, Litmathe\u00a0J (2018) Orale Antikoagulation mit Vitamin K\u2011Antagonisten \u2013 ein Update. Wien Med Wochenschr 168(5\u20136):121\u2013132","journal-title":"Wien Med Wochenschr"},{"issue":"Suppl 6","key":"1751_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15006-019-0920-y","volume":"161","author":"C Sucker","year":"2019","unstructured":"Sucker\u00a0C, Litmathe\u00a0J, Berthold\u00a0HK (2019) Orale Antikoagulation bei Vorhofflimmern: Differentialtherapie mit Nicht-Vitamin-K-abh\u00e4ngigen oralen Antikoagulanzien (NOAK) und Vitamin-K-Antagonisten (VKA) [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)]. MMW Fortschr Med 161(Suppl 6):15\u201323","journal-title":"MMW Fortschr Med"},{"key":"1751_CR54","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1111\/aos.14563","volume":"99","author":"DA Wenzel","year":"2021","unstructured":"Wenzel\u00a0DA, Kromer\u00a0R, Poli\u00a0S et al (2021) Optical coherence tomography-based determination of ischaemia onset\u2014the temporal dynamics of retinal thickness increase in acute central retinal artery occlusion. Acta Ophthalmol 99:e247\u2013e252. https:\/\/doi.org\/10.1111\/aos.14563","journal-title":"Acta Ophthalmol"},{"key":"1751_CR55","first-page":"84","volume":"23","author":"E Xourgia","year":"2022","unstructured":"Xourgia\u00a0E, Tektonidou\u00a0MG (2022) An update on Antiphospholipid syndrome. Curr Rheumatol 23:84","journal-title":"Curr Rheumatol"},{"key":"1751_CR56","first-page":"3","volume":"13","author":"RB Zotz","year":"2009","unstructured":"Zotz\u00a0RB, Sucker\u00a0C, Gerhardt\u00a0A (2009) Bedeutung thrombophiler Risikofaktoren f\u00fcr das Erst- und Rezidivthromboserisiko. H\u00e4motherapie 13:3\u201319","journal-title":"H\u00e4motherapie"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01751-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-022-01751-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01751-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:15:19Z","timestamp":1668712519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-022-01751-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1007\/s00347-022-01751-y","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"13 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Sucker: Vortr\u00e4ge: Leo Pharma, Sanofi, STAGO, Werfen; Advisory Boards: Werfen. N.\u00a0Feltgen: Consultant: Alimera Sciences, Chiesi, Novartis, Roche; Speaker: Allergan\/AbbVie, Alimera, Apellis, Bayer, Heidelberg Engineering, Novartis, Roche. L.\u2011O.\u00a0Hattenbach: Studienteilnahme, Referent\/Berater: Novartis Pharma GmbH, Bayer AG, Pharm Allergan GmbH, Roche Pharma AG; Studienteilnahme Apellis, Chengdu Kanghong Biotech Co., Ltd. C.\u00a0Kuhli-Hattenbach, M.\u00a0Spitzer und M.\u00a0Schultheiss geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}